Moderate wine consumption is linked to a lower incidence of coronary heart disease, with various commercial wines tested for their inhibitory effects on certain enzymes related to platelet aggregation. The study highlighted the presence of phenolic compounds in wine, such as resveratrol, which can decrease platelet aggregation and inflammatory mediators. The results suggest that both alcohol and these compounds in wine contribute to reduced cardiovascular risks.

1. Moderateconsumptionofwineisassociatedwithreducedincidenceofcoronaryheartdiseases.
http://dx.doi.org/10.1155/2014/178931
SamplesofcommercialwinesfromdifferentregionsofGeorgia,CzechRepublic,France,Italy,and
Austriawereprovidedbylocalproducersorpurchasedfromsupermarketsorwinestores.
ThewinesweretestedasacomplexmixtureofvariouscompoundsforitsinhibitorypotentialtowardsCOX-1,COX-2and
5-LOX.TheGeorgianredandwhitewineswithwinesproducedincentralandwesternEuropewerecompared.Also,the
inihibitoryactivityof33phenoliccompoundscommonlyoccuringinwinewerealsodetermined.
Plateletaggregationcouldbe
decreasedbytheinhibition
ofcyclooxygenase-1(COX-1)
activitybyphenoliccompounds
presentinwine,suchasresveratrol.
Thesewineconstituentsare
abletoinhibit5-LOXactivity.
Itcatalyzesbiosynthesesof
thromboxanes,eicosanoids
propagatingplateletaggregation
andvasoconstriction.
Animportantbiosynthetic
pathwayleadingtotheproduction
ofeicosanoids.Thefinalproduct
ofthe5-LOXpathway,leukotriene
B4(LTB4),isamediatorof
severalinflammatorydiseases
includingatherosclerosis.
Alcoholpresentinwinedecreases
plateletaggregation,resultingin
reducedadherencetotheendothelial
surfaceofthearteries,blood
coagulation,andthrombusformation.
PinotNoir(n=5),CabernetSauvignon(n=7),
CabernetMoravia(n=2),Seperavi(n=9),CuveeofSeperaviand
SeperaviBudeshuriseburi(n=2),Alexandrouli(n=1).
Chardonnay(n=6),SauvignonBlanc(n=3),Rkatsiteli(n=2),
CuveeofRkatsiteliandotherlocalvaieties(n=2)
RamVesicles Human
Recombinant
addto180uLofincubation
mixturecomposingof:
100mMtrisbuffer(pH8.0)
5uMporcineshematin
18mML-epinephrine
50uMSodiumEDTA
Obtainbuffycoatfromhealthy
donorsandsedimentitin20mL
dextransolutionat4C.
Centrifugeandwashthepellet
withphosphatebuffersaline.
Dilutesamplesto1:15withELISAbufferanddetermine
thePGE2producedwiththePGE2ELISAkit
MeasuretherelativePGE2concentrationwitha
microplatereaderTecanInfiniteM200at405nm.
Add5uLof10uMArachidonicacidtostartthereaction.
Incubatefor20minsat37C
Stopthereactionwith10uLof10%formicacid.
MeasuretherelativeLTB4concentrationwitha
microplatereaderTecanInfiniteM200at405nm.
Dilutesamples40timesinELISAbufferanddetermine
theconcentrationofLTB4withtheLTB4ELISAkit
Add5uLof10uMArachidonicacidtostartthereaction.
Incubatefor20minsat37C
Stopthereactionwith10uLof10%formicacid.
addto225uLofincubation
mixturecomposingof:
10uLof2mMCalciumChloride
10uLof10uMETYA